Angela Hwang: Yes. So it’s still early days, especially in the U.S., right, because that’s only happening middle of the year. But what I can say is that we have had some early discussions already with agencies and reimbursement agencies outside of the U.S. who have given us, I guess, earlier feedback. And even if you take a country like the U.K., we actually had very favorable feedback on the pricing that we provided, and they agreed with the cost effectiveness of our Paxlovid. So I think we’ll — obviously, that’s good feedback, and we’ll be taking those learnings and those value arguments to multiple countries around the world.
Operator: Our next question will come from Carter Gould with Barclays.
Carter Gould: Thanks for taking the questions. And David, thank you for all the transparency on the underlying assumptions. I guess, two for me. First off, just in terms of the upcoming, I guess, messaging around the end of the public health emergency. Can you talk about the potential impact you see on your EUAs, access as well, specifically thinking about Paxlovid populations in this period before we switch to a commercial market where you’re still — the government is still, I guess, working through the inventory they have in hand? And then, going to the COVID/flu combination, just trying to better understand some of your assumptions here. Because I guess when we think about that €˜26 40% adoption number, — it’s some — I guess, either the incremental bump from €˜24, 15% or the 40% absolute, just kind of what that implies about how you think the underlying flu market will change.
I guess, that complies 30% to 80% share within two years, but just wanted to understand kind of the underlying drivers there and how you think about that market evolving.
Dr. Albert Bourla: Thank you. Maybe I try myself quickly because we’re running out of time. If there is an end of emergency, we don’t think that will have any impact on current in U.S., will have an impact on issuing new in U.S. I don’t think that anything changes in the way that — emergency or not, whether the inventories will be managed or the access that patients will have in any of these treatments. Now, as regards of COVID/flu, if the introduction of combination for products would change the flu market, I think, yes — well, would say it’s a major flu market was always a single market until now. And suddenly, there is a chance that other respiratory cases like COVID or RSV will come. So I think that would change. But now, the step-up, it is clear we expect that around 24%, 25%, it is a population in the U.S., that believes needs protection and is diligent enough — not believes, more belief, but they are diligent enough to follow the recommendation and go and get their annual booster for COVID.
When they will present themselves — excuse me, when the flu people will present themselves and they will be asked that question, if you want flu single or flu with a combo, and they will be given the information that will protect them in a single injection at the same time, zero co-pay, for COVID as well, we believe it’s reasonable to expect that the 25% stable will become 30%, so we’ll add another 5% of the population. And that over time, that will move closer to the 50%, we project 40 over there. So, those are the assumptions that we’re using. Next question, please.
Operator: Our next question will come from Kerry Holford with Berenberg.
